Tinnitus - Pipeline Insight, 2024

This “Tinnitus - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in Tinnitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tinnitus: Understanding

Tinnitus: Overview

Tinnitus is a condition characterized by the perception of sound within the ears or head without any external source. Most cases of tinnitus are subjective, meaning only the individual experiencing it can hear the sound. This type of tinnitus cannot be heard by an examiner or measured using tools. On the other hand, objective tinnitus is a rare form where the examiner can hear the sound. Objective tinnitus can be caused by various underlying conditions, one of which is an aneurysm. In this case, the sound can be objectified and heard by a healthcare provider. Other causes of objective tinnitus include temporomandibular joint disease (TMJD) and tensor tympani muscle spasm. These conditions can lead to sounds that are audible to others and can be detected during a medical examination.

Tinnitus, the perception of sound without an external source, has various etiologies. It can be caused by factors such as noise trauma, metabolic diseases like heart conditions and diabetes, ear diseases including Meniere's disease, and even rare conditions like Chiari malformation. Additionally, tinnitus can result from issues like temporomandibular joint disease (TMJD) and tensor tympani muscle spasm. Furthermore, tinnitus can be subjective, where only the individual perceives the sound, or objective, where the sound can be heard by an examiner. Objective tinnitus can be linked to conditions like aneurysms. Understanding the diverse causes and manifestations of tinnitus is crucial for effective diagnosis and management in clinical settings.

Many commonly prescribed medications, particularly antineoplastic drugs used in cancer treatment, can cause ototoxicity leading to hearing loss and tinnitus. Platinum-based chemotherapeutics like cisplatin and carboplatin are among the most ototoxic agents, with incidence rates ranging from 45% to 83.3% for cisplatin alone and 16.6% to 75% when combined with carboplatin. Other ototoxic antineoplastic drugs include bleomycin, methotrexate, and nitrogen mustard. Diuretics such as ethacrynic acid and acetazolamide have also been associated with ototoxicity. Aspirin in high doses can induce tinnitus, but this effect is typically reversible upon discontinuation of the medication. However, caution is warranted when evaluating tinnitus potentially caused by a new drug, as tinnitus is highly prevalent in the general population, and placebo-controlled studies have reported tinnitus in both treatment and placebo groups. When using ototoxic antineoplastic drugs, regular hearing assessments are crucial to monitor for the development of hearing loss or tinnitus, allowing for prompt intervention and potential modification of the treatment regimen if necessary.

The American Academy of Otolaryngology's clinical practice guidelines for tinnitus emphasize stress reduction techniques like biofeedback and cognitive therapy to alleviate the negative impact of tinnitus. Masking techniques involving the introduction of various sounds, including white noise or music, can help distract from internal tinnitus sounds. Sleep improvement strategies are crucial due to tinnitus's effect on sleep quality. While medications like alprazolam and antidepressants may be used for symptom management, the guidelines stress that no medication can cure tinnitus. Additionally, the guidelines highlight the importance of individualized programs, such as Tinnitus Retraining Therapy and Neuronomics, to help patients manage and cope with tinnitus effectively.

"Tinnitus - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tinnitus R&D. The therapies under development are focused on novel approaches to treat/improve Tinnitus.

Tinnitus Emerging Drugs Chapters

This segment of the Tinnitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tinnitus Emerging Drugs

Keyzilen: Altamira Therapeutics

Keyzilen, Esketamine gel for injection, developed for the treatment of acute inner ear tinnitus. Esketamine is a potent, small molecule NMDA receptor antagonist. The drug is administered via three intratympanic injections over 3-5 days. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Tinnitus.

Tinnitus: Therapeutic Assessment

This segment of the report provides insights about the different Tinnitus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tinnitus

There are approx. 7+ key companies which are developing the therapies for Tinnitus. The companies which have their Tinnitus drug candidates in the most advanced stage, i.e. Phase III include, Altamira Therapeutics.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tinnitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tinnitus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tinnitus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tinnitus drugs.

Tinnitus Report Insights

• Tinnitus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tinnitus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tinnitus drugs?
• How many Tinnitus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tinnitus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tinnitus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tinnitus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Altamira Therapeutics
• Sage Therapeutics
• Gateway Biotechnology

Key Products

• Keyzilen
• Brexanolone
• GW-TT2

This product will be delivered within 2 business days.